Alnylam to file rare kidney disease drug after trial winAfter years where RNA interference research was in the doldrums, Alnylam is on a roll and is preparing Share XAlnylam to file rare kidney disease drug after trial winhttps://pharmaphorum.com/news/alnylam-to-file-rare-kidney-disease-drug-after-phase-3-win/
FDA approves Alnylam’s second RNAi drug – with $442K annual price tagAlnylam has had a second RNA interference (RNAi) drug approved by the FDA, to treat the ultra-rare disease Share XFDA approves Alnylam’s second RNAi drug – with $442K annual price taghttps://pharmaphorum.com/news/fda-approved-alnylams-second-rnai-drug/
NICE restores parity between Alnylam and Akcea on rare diseaseNICE has reversed its stance on Alnylam’s gene-silencing drug Onpattro for rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), Share XNICE restores parity between Alnylam and Akcea on rare diseasehttps://pharmaphorum.com/news/nice-restores-parity-between-alnylam-and-akcea-on-rare-disease/
NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
Alnylam to file gene-silencing porphyria drugAlnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying Share XAlnylam to file gene-silencing porphyria drughttps://pharmaphorum.com/news/alnylam-to-file-gene-silencing-porphyria-drug/
R&D Roundup: Pharma gets in on the biotech boomSome good news for the UK industry in turbulent times is always welcome, and several announcement this month Share XR&D Roundup: Pharma gets in on the biotech boomhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-pharma-gets-in-on-the-biotech-boom/
Regeneron and Alnylam announce $1bn collaborationRegeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and Share XRegeneron and Alnylam announce $1bn collaborationhttps://pharmaphorum.com/news/regeneron-and-alnylam-announce-1bn-collaboration/
Sanofi and Alnylam conclude research phase of RNAi allianceSanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance Share XSanofi and Alnylam conclude research phase of RNAi alliancehttps://pharmaphorum.com/news/sanofi-and-alnylam-conclude-research-phase-of-rnai-alliance/
FDA approves Ionis/Akcea’s Tegsedi RNAi drug, taking on AlnylamThe FDA has approved Ionis Pharmaceuticals’ RNA silencing drug Tegsedi (inotersen) for nerve damage caused by a rare Share XFDA approves Ionis/Akcea’s Tegsedi RNAi drug, taking on Alnylamhttps://pharmaphorum.com/news/fda-approves-ionis-akceas-tegsedi-competing-against-alnylam/
